期刊文献+

尼妥珠单抗联合DCF方案治疗晚期胃癌1例

暂未订购
导出
摘要 随着新的化疗药物的不断出现,晚期胃癌的化疗已经具有较多的选择。但是,无论是在近期疗效还是在远期生存期上,其结果尚未能令人满意。靶向表皮生长因子受体(EGFR)药物的问世,使多种实体肿瘤的治疗效果得到了明显的提高。我科采用尼妥珠单抗联合DCF方案治疗晚期残胃癌伴肝多发转移1例取得良好的疗效,现报告如下。
出处 《癌症进展》 2011年第4期453-454,共2页 Oncology Progress
  • 相关文献

参考文献5

  • 1Cutsem E V. Novel cytotoxic regimens in gastric cancer [J]. Eur J Cancer Supplements. 2006, 4 (10): 14.
  • 2Ozdemir NY, Aball H, Budakoglu B, et al. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-flu- orouracil in the first-line treatment of advanced stage gastric [J]. Med Oncol, 2009, Epub ahead of print.
  • 3Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity [ J ]. Expert Opin Biol Ther,2009, 9 (9):1199.
  • 4Pinto C, Siena S, Barone C, et al. Cetuximab in combi- nation with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gas- troesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study) [ J ]. J Clin Oncol, 2008, 26 (suppl) : Abstr 4575.
  • 5Rao S, Starling N, Cunningham D, et al. Phase I study of epirubicin, cisplatin and eapecitabine plus matuzumab in previously untreated patients with advanced oesophagogastrie cancer [ J]. Br J Cancer, 2008, 99 (6) : 868.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部